-
Bellicum Rallies After FDA Lifts Clinical Hold
Thursday, April 12, 2018 - 1:01pm | 362Read More...Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) stock jumped more than 16 percent on Thursday after the company announced on Wednesday afternoon that the Food and Drug Administration lifted a clinical hold on the company’s BPX-501 study. Wells Fargo upgraded Bellicum to Outperform on Thursday,...
-
Bellicum Pharmaceuticals Q1 Miss Doesn't Matter, As Long As Pipeline Remains On Track
Tuesday, May 9, 2017 - 12:19pm | 385Read More...Quarterly earnings reports matter a lot more for some companies than others. According to Wall Street analysts, investors should look beyond Bellicum Pharmaceuticals Inc (NASDAQ: BLCM)’s first-quarter earnings miss and focus on its drug pipeline, which includes leading cancer treatment...
-
Bellicum Pharmaceuticals Gains 8%, Company Receives Orphan Drug Designation For Its BPX-501 Therapy
Monday, February 22, 2016 - 2:12pm | 234Read More...Shares of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) were trading higher by 8 percent on Monday after the company announced that the U.S. Food and Drug Administration (FDA) granted its BPX-501 with an orphan drug designation. The FDA designation is for the combination of BPX-501 genetically...
